Isolation of generator-produced 223Ra in 0.9-% NaCl solutions containing EDTA for direct radiotherapeutic studies

Mokhodoeva, O. B.; Guseva, L. I.; Dogadkin, N. N.

doi:10.1007/s10967-014-3777-7

Cited by 15 publications

(9 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Here we performed chemical separation of 223 Ra on the kBq scale from cyclotron-produced 227 Ac (Figure 1B). Previous 223 Ra purifications utilize this strategy to produce GBq of 223 Ra starting from pure 227 Ac source material (Mokhodoeva et al, 2015; Soderquist et al, 2012). …”

Section: Resultsmentioning

confidence: 99%

“…Radiochemical separation of GBqs of 223 Ra starting from sources of ultra-pure 227 Ac and 227 Th has previously been described (Mokhodoeva et al, 2015; Soderquist et al, 2012). Briefly, this purification utilized ionic exchange resins to separate 227 Ac and 227 Th from 223 Ra-nitrate complexes based on charge discrepancies (Boll et al, 2005).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Radium-223 microgenerator from cyclotron-produced trace Actinium-227

Abou

Pickett

Mattson

et al. 2017

Applied Radiation and Isotopes

View full text Add to dashboard Cite

The alpha particle emitter Radium-223 dichloride (223RaCl2) has recently been approved for treatment of late-stage bone metastatic prostate cancer. There is considerable interest in studying this new agent outside of the clinical setting, however the supply of 223Ra is limited and expensive. We have engineered a 223Ra microgenerator using traces of 227Ac previously generated from cyclotron-produced 225Ac. Radiochemically pure 223RaCl2 was made, characterized, evaluated in vivo, and the source was recovered in high yield for regeneration of the microgenerator.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A Radium-223 microgenerator from cyclotron-produced trace Actinium-227

Abou

Pickett

Mattson

et al. 2017

Applied Radiation and Isotopes

View full text Add to dashboard Cite

show abstract

“…213 Bi forms stable complexes with nitrogen-rich chelators such (23). Parent isotopes are loaded on actinide chromatographic resin, and 223 Ra-chloride solution is obtained after elution with 1 M HCl or HNO 3 , subsequent purification on a cation exchange column, evaporation, and dissolution in saline solution (24).…”

Section: Atmentioning

confidence: 99%

α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies—Part 1

et al. 2018

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to (1) cite α-emitter families available for therapeutic use and understand their current production limit; (2) consider radiation safety concerns when handling α-emitters; and (3) overcome radiolabeling and daughter redistribution hurdles with the approaches described in this educational review. CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, SAM, and other credit types, participants can access this activity through the SNMMI website (http://www.snmmilearningcenter.org) through June 2021.With a short particle range and high linear energy transfer, α-emitting radionuclides demonstrate high cell-killing efficiencies. Even with the existence of numerous radionuclides that decay by α-particle emission, only a few of these can reasonably be exploited for therapeutic purposes. Factors including radioisotope availability and physical characteristics (e.g., half-life) can limit their widespread dissemination. The first part of this review will explore the diversity, basic radiochemistry, restrictions, and hurdles of α-emitters. Radi onuclide strategies for curative therapy, disease control, or palliation are positioned to constitute a major portion of nuclear medicine. The range of available therapeutic radioisotopes, including a, b, or Auger electron emission, has considerably expanded over the last century (1). Matching the particle decay pathway, effective range, and relative biological effectiveness to tumor mass, size, radiosensitivity, and heterogeneity is the primary consideration for maximizing therapeutic efficacy. b-emitting radioisotopes have the longest particle pathlength (#12 mm) and lowest linear energy transfer (LET) (;0.2 keV/mm), supporting their effectiveness in medium to large tumors (Fig. 1). Although the long b-particle range is advantageous in evenly distributing radiation dose in heterogeneous tumors, it can also result in the irradiation of healthy tissue surrounding the tumor site. Conversely, Auger electrons have high LET (4-26 keV/mm) but a limited pathlength of 2-500 nm that restricts their efficacy to single cells, thus requiring the radionuclide to cross the cell membrane and reach the nucleus. Finally, a-particles have a moderate pathlength (50-100 mm) and high LET (80 keV/mm) that render them especially suitable for small neoplasms or micrometastases. A recent clinical study highlighted the ability of a-radiotherapy to overcome treatment resistance to b-particle therapy, prompting a paradigm shift in the approach toward radionuclide therapy (2).For optimized therapeutic efficacy, the a-cytotoxic payload is expected to accumulate selectively in diseased tissue and deliver a suf...

show abstract

“…Clinical production of 223 Ra uses 227 Ac/ 227 Th–based generators . Parent radionuclides are loaded on actinide chromatographic resin, and 223 Ra chloride solution is obtained after elution therefrom with 1.0M HCl or HNO 3 , subsequent use of cation exchange, evaporation, and dissolution in saline solution …”

Section: Radiometals For Theranostic Applicationsmentioning

confidence: 99%

Radiometals for imaging and theranostics, current production, and future perspectives

Mikołajczak

Meulen

Lapi

2019

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

The aim of this review is to make the reader familiar with currently available radiometals, their production modes, capacities, and quality concerns related to their medical use, as well as new emerging radiometals and irradiation technologies from the perspective of their diagnostic and theranostic applications. Production methods of 177Lu serve as an example of various issues related to the production yield, specific activity, radionuclidic and chemical purity, and production economy. Other radiometals that are currently used or explored for potential medical applications, with particular focus on their theranostic value, are discussed. Using radiometals for diagnostic imaging and therapy is on the rise. The high demand for radiometals for medical use prompts investigations towards using alternative irradiation reactions, while using existing nuclear reactors and accelerator facilities. This review discusses these production capacities and what is necessary to cover the growing demand for theranostic nuclides.

show abstract

Isolation of generator-produced 223Ra in 0.9-% NaCl solutions containing EDTA for direct radiotherapeutic studies

Cited by 15 publications

References 11 publications

A Radium-223 microgenerator from cyclotron-produced trace Actinium-227

A Radium-223 microgenerator from cyclotron-produced trace Actinium-227

α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies—Part 1

Radiometals for imaging and theranostics, current production, and future perspectives

Contact Info

Product

Resources

About